-
-
-
-
-
-
-
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
-
-
-
-
-
-
-
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
-
-
-
-
-
-
-
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
-
-
-
-
-
-
-
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
-
-
-
-
-
-
-
Akari Therapeutics names Kameel Farag as interim CFO
-
-
-
-
-
-
-
Akari Therapeutics forms advisory board, appoints oncologist Hurvitz
-
-
-
-
-
-
-
Akari Therapeutics reports preclinical data on prostate cancer payload
-
1,197,437 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

